{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:44:18Z","timestamp":1786160658621,"version":"build-2736575974"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.intimp.2025.115162","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:27:30Z","timestamp":1751617650000},"page":"115162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Toward immune tolerance in rheumatoid arthritis: Emerging immunotherapies and targets for long-term remission"],"prefix":"10.1016","volume":"162","author":[{"given":"Ali","family":"Afshari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khorramdelazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Abbasifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115162_bb0005","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","article-title":"The burden of disease in rheumatoid arthritis","volume":"32","author":"Uhlig","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.intimp.2025.115162_bb0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13105-012-0216-5","article-title":"Inflammation and rheumatoid arthritis","volume":"69","author":"Shrivastava","year":"2013","journal-title":"J. Physiol. Biochem."},{"issue":"6","key":"10.1016\/j.intimp.2025.115162_bb0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115162_bb0025","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrrheum.2017.107","article-title":"Antigen-specific immunotherapies in rheumatic diseases","volume":"13","author":"Pozsgay","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2025.115162_bb0035","series-title":"WILEY 111 RIVER ST, HOBOKEN 07030\u20135774","author":"Luu","year":"2023"},{"key":"10.1016\/j.intimp.2025.115162_bb0040","article-title":"IAP antagonists potentiate TNF\u03b1-triggered apoptosis but selectively eliminate senescent tumor cells independently of TNF\u03b1","author":"Ochiiwa","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.intimp.2025.115162_bb0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/annrheumdis-2024-eular.5053","article-title":"POS0457 re-education of innate immunity in rheumatoid arthritis by JAK inhibitors","volume":"83","author":"Lopez-Navarro","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2025.115162_bb0050","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2665-9913(20)30344-1","article-title":"Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy","volume":"2","author":"Nel","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.intimp.2025.115162_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1012868","article-title":"Reestablish immune tolerance in rheumatoid arthritis","volume":"13","author":"Shuai","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0060","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1136\/ard.2011.151654","article-title":"Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?","volume":"70","author":"Stoop","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2025.115162_bb0065","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2018.01169","article-title":"Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials","volume":"9","author":"Fl\u00f3rez-Grau","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cei\/uxac115","article-title":"Antigen-specific immunotherapy to restore antigen-specific tolerance in type 1 diabetes and graves' disease","volume":"211","author":"Zala","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.621774","article-title":"Peptide-MHC-based nanomedicines for the treatment of autoimmunity: engineering, mechanisms, and diseases","volume":"11","author":"Serra","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115162_bb0080","first-page":"2069","article-title":"Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice","volume":"6","author":"Pletinckx","year":"2022","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1084\/jem.20182287","article-title":"Taming autoimmunity: translating antigen-specific approaches to induce immune tolerance","volume":"216","author":"Carballido","year":"2019","journal-title":"J. Exp. Med."},{"issue":"290","key":"10.1016\/j.intimp.2025.115162_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"18","key":"10.1016\/j.intimp.2025.115162_bb0095","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126025","article-title":"PD-L1\u2013and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease","volume":"4","author":"Galea","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2025.115162_bb0100","series-title":"Translational Autoimmunity","first-page":"207","article-title":"A tolerogenic dendritic cell\u2013based therapy targeting heat shock protein\u2013specific regulatory T cells in rheumatoid arthritis","author":"Stoppelenburg","year":"2023"},{"key":"10.1016\/j.intimp.2025.115162_bb0105","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3389\/fimmu.2019.02068","article-title":"Matured tolerogenic dendritic cells effectively inhibit autoantigen specific CD4+ T cells in a murine arthritis model","volume":"10","author":"Jansen","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0110","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1111\/j.1750-3841.2009.01457.x","article-title":"Bioavailability and delivery of nutraceuticals using nanotechnology","volume":"75","author":"Huang","year":"2010","journal-title":"J. Food Sci."},{"key":"10.1016\/j.intimp.2025.115162_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864403","article-title":"Nanoparticles for inducing antigen-specific T cell tolerance in autoimmune diseases","volume":"13","author":"Benne","year":"2022","journal-title":"Front. Immunol."},{"issue":"7591","key":"10.1016\/j.intimp.2025.115162_bb0120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.intimp.2025.115162_bb0125","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1073\/pnas.96.26.15050","article-title":"Abundant empty class II MHC molecules on the surface of immature dendritic cells","volume":"96","author":"Santambrogio","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.115162_bb0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.immuni.2006.11.007","article-title":"The ins and outs of MHC class II proteins in dendritic cells","volume":"25","author":"Santambrogio","year":"2006","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0135","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/ncomms5741","article-title":"Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy","volume":"5","author":"Burton","year":"2014","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.intimp.2025.115162_bb0140","first-page":"20119","article-title":"Autoantigenic peptide and immunomodulator codelivery system for rheumatoid arthritis treatment by reestablishing immune tolerance","volume":"16","author":"Mai","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"20","key":"10.1016\/j.intimp.2025.115162_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160964","article-title":"Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide\/calcitriol liposomes in ACPA+ rheumatoid arthritis","volume":"7","author":"Sonigra","year":"2022","journal-title":"JCI Insight"},{"issue":"25","key":"10.1016\/j.intimp.2025.115162_bb0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218668120","article-title":"Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis","volume":"120","author":"Urbonaviciute","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0155","first-page":"449","article-title":"Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial","volume":"30","author":"Kavanaugh","year":"2003","journal-title":"J. Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115162_bb0160","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kew287","article-title":"Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I\/IIA RAGULA clinical trial in rheumatoid arthritis","volume":"55","author":"Kirkham","year":"2016","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2018.042","article-title":"Vaccination with a novel antigen-specific tolerizing DNA vaccine encoding CCOL2A1 protects rats from experimental rheumatoid arthritis","volume":"30","author":"Zhao","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.intimp.2025.115162_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112294","article-title":"Different protective efficacies of a novel antigen-specific DNA vaccine encoding chicken type II collagen via intramuscular, subcutaneous, and intravenous vaccination against experimental rheumatoid arthritis","volume":"144","author":"Zhao","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0175","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41467-023-36620-y","article-title":"Citrullination modulates antigen processing and presentation by revealing cryptic epitopes in rheumatoid arthritis","volume":"14","author":"Curran","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0180","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/annrheumdis-2013-203844","article-title":"Citrullination of autoantigens implicates NETosis in the induction of autoimmunity","volume":"73","author":"Dwivedi","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"178","key":"10.1016\/j.intimp.2025.115162_bb0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005580","article-title":"NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis","volume":"5","author":"Khandpur","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00018-022-04126-3","article-title":"Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives","volume":"79","author":"Ciesielski","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/art.24139","article-title":"Tolerization with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-\u03b3, interleukin-17, and antibody responses","volume":"60","author":"Satpute","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0200","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrrheum.2018.10","article-title":"The B cell response to citrullinated antigens in the development of rheumatoid arthritis","volume":"14","author":"Scherer","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10086","key":"10.1016\/j.intimp.2025.115162_bb0205","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105164","article-title":"Antigen-specific tolerance approach for rheumatoid arthritis: past, present and future","volume":"88","author":"Page","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2025.115162_bb0215","series-title":"Bone Loss, Pain and Inflammation: Three Faces of ACPA in RA Pathogenesis","first-page":"637","author":"Sokolove","year":"2016"},{"issue":"7","key":"10.1016\/j.intimp.2025.115162_bb0220","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41573-024-00953-0","article-title":"Navigating the complexities of drug development for inflammatory bowel disease","volume":"23","author":"Honap","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0225","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/1529-0131(199802)41:2<290::AID-ART13>3.0.CO;2-R","article-title":"Treatment of rheumatoid arthritis with oral type II collagen: results of a multicenter, double-blind, placebo-controlled trial","volume":"41","author":"Barnett","year":"1998","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"issue":"11","key":"10.1016\/j.intimp.2025.115162_bb0230","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.24916","article-title":"Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial","volume":"60","author":"Koffeman","year":"2009","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0235","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41584-021-00585-3","article-title":"The gut\u2013joint axis in rheumatoid arthritis","volume":"17","author":"Zaiss","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115162_bb0240","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrrheum.2016.85","article-title":"How the microbiota shapes rheumatic diseases","volume":"12","author":"Van de Wiele","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115162_bb0245","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: a pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"The lancet Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0250","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41423-023-00987-1","article-title":"Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity","volume":"20","author":"Kim","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0255","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/microorganisms9051070","article-title":"Probiotics and amelioration of rheumatoid arthritis: significant roles of lactobacillus casei and lactobacillus acidophilus","volume":"9","author":"Paul","year":"2021","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/27697061.2023.2211129","article-title":"Microbial imbalance and intestinal permeability in the pathogenesis of rheumatoid arthritis: a mechanism review with a focus on bacterial translocation, citrullination, and probiotic intervention","volume":"43","author":"Blenkinsopp","year":"2024","journal-title":"Journal of the american nutrition association"},{"key":"10.1016\/j.intimp.2025.115162_bb0265","first-page":"1092118","article-title":"Gut-joint axis: gut dysbiosis can contribute to the onset of rheumatoid arthritis via multiple pathways. Frontiers in cellular and infection","volume":"13","author":"Romero-Figueroa","year":"2023","journal-title":"Microbiology"},{"issue":"8","key":"10.1016\/j.intimp.2025.115162_bb0270","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.4049\/jimmunol.145.8.2489","article-title":"Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen","volume":"145","author":"Zhang","year":"1990","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"7","key":"10.1016\/j.intimp.2025.115162_bb0275","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in graves' hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0280","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s42003-024-06476-z","article-title":"Undenatured type II collagen protects against collagen-induced arthritis by restoring gut-joint homeostasis and immunity","volume":"7","author":"Pan","year":"2024","journal-title":"Communications Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2025.115162_bb0290","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2015.1073425","article-title":"Safety and immunogenicity of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats","volume":"11","author":"Juan","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2025.115162_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4130","article-title":"Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis","volume":"15","author":"Thomas","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2025.115162_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1049","article-title":"Human cartilage glycoprotein 39-directed T cell responses in health and arthritic diseases","volume":"6","author":"Bilsen","year":"2004","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0305","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.4049\/jimmunol.147.9.3031","article-title":"Characterization of the autoantigen calreticulin","volume":"147","author":"Rokeach","year":"1991","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"12","key":"10.1016\/j.intimp.2025.115162_bb0310","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.3390\/ijms24129884","article-title":"Significance of type II collagen posttranslational modifications: from autoantigenesis to improved diagnosis and treatment of rheumatoid arthritis","volume":"24","author":"Batsalova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0315","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri2153","article-title":"Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease","volume":"7","author":"Miller","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-02169-0","article-title":"Cartilage-binding antibodies initiate joint inflammation and promote chronic erosive arthritis","volume":"22","author":"Li","year":"2020","journal-title":"Arthritis Res. Ther."},{"issue":"49","key":"10.1016\/j.intimp.2025.115162_bb0325","doi-asserted-by":"crossref","first-page":"17180","DOI":"10.1073\/pnas.0407704101","article-title":"Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis","volume":"101","author":"van Bilsen","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2025.115162_bb0330","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/ar1125","article-title":"Application of regulatable vectors in gene therapy of experimental arthritis","volume":"6","author":"Gould","year":"2004","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0335","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00002281-200205000-00011","article-title":"Genetics of rheumatoid arthritis: is there a scientific explanation for the human leukocyte antigen association?","volume":"14","author":"Buckner","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"issue":"24","key":"10.1016\/j.intimp.2025.115162_bb0340","doi-asserted-by":"crossref","first-page":"15803","DOI":"10.3390\/ijms232415803","article-title":"Implications of post-translational modifications in autoimmunity with emphasis on citrullination, homocitrullination and acetylation for the pathogenesis, diagnosis and prognosis of rheumatoid arthritis","volume":"23","author":"Haro","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2025.115162_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202100056","article-title":"Targeting lymphoid tissues to promote immune tolerance","volume":"4","author":"Chen","year":"2021","journal-title":"Adv. Therapeutics"},{"key":"10.1016\/j.intimp.2025.115162_bb0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0167-5699(90)90050-J","article-title":"Heat shock proteins and the immune response","volume":"11","author":"Kaufmann","year":"1990","journal-title":"Immunol. Today"},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0355","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.3390\/ijms24054296","article-title":"Characteristics of the (auto) reactive T cells in rheumatoid arthritis according to the immune epitope database","volume":"24","author":"Carl\u00e9","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115162_bb0360","first-page":"1","article-title":"Antigen-driven T cell responses in rheumatic diseases: insights from T cell receptor repertoire studies","author":"Garrido-Mesa","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2025.115162_bb0365","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/ar1558","article-title":"Functional regulatory immune responses against human cartilage glycoprotein-39 in health versus proinflammatory responses in rheumatoid arthritis","volume":"7","author":"van Bilsen","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0370","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/art.20106","article-title":"Effector function of type II collagen\u2013stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts","volume":"50","author":"Cho","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2025.115162_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1217","article-title":"Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells","volume":"6","author":"Nandakumar","year":"2004","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0380","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1021\/acschembio.8b01018","article-title":"Exploiting CD22 to selectively tolerize autoantibody producing B-cells in rheumatoid arthritis","volume":"14","author":"Bednar","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0385","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cei.12038","article-title":"Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?","volume":"172","author":"Hilkens","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0390","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41423-023-00989-z","article-title":"AT follicular helper cell origin for T regulatory type 1 cells","volume":"20","author":"Sol\u00e9","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0395","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0065-2776(10)05004-2","article-title":"The family of IL-10-secreting CD4+ T cells","volume":"105","author":"Fujio","year":"2010","journal-title":"Adv. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115162_bb0400","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115162_bb0405","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0410","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.jaci.2017.12.984","article-title":"Intestinal IFN-\u03b3\u2013producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease","volume":"142","author":"Alfen","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0415","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1038\/s41467-018-07581-4","article-title":"Molecular and functional heterogeneity of IL-10-producing CD4+ T cells","volume":"9","author":"Brockmann","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115162_bb0420","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fimmu.2016.00355","article-title":"Tr1-like T cells\u2013an enigmatic regulatory T cell lineage","volume":"7","author":"White","year":"2016","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0425","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41587-019-0015-4","article-title":"Antigen-specific therapeutic approaches for autoimmunity","volume":"37","author":"Serra","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2025.115162_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684240","article-title":"Re-programming autoreactive T cells into T-regulatory type 1 cells for the treatment of autoimmunity","volume":"12","author":"Sol\u00e9","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0435","doi-asserted-by":"crossref","first-page":"1334281","DOI":"10.3389\/fimmu.2024.1334281","article-title":"Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines","volume":"15","author":"Zimmerman","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0440","series-title":"Seminars in Immunology","article-title":"Type 1 regulatory T cells (Tr1) in autoimmunity","author":"Pot","year":"2011"},{"key":"10.1016\/j.intimp.2025.115162_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2128-4","article-title":"Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis","volume":"17","author":"Spiering","year":"2019","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0450","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.115162_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102333","article-title":"Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases","volume":"104","author":"Huang","year":"2019","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0460","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"20","key":"10.1016\/j.intimp.2025.115162_bb0465","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"},{"issue":"17","key":"10.1016\/j.intimp.2025.115162_bb0470","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","article-title":"A Phase I Study of APX005M and Cabiralizumab With or Without Nivolumab in Patients With Melanoma, Kidney Cancer, or Non\u2013Small Cell Lung Cancer Resistant to Anti-PD-1\/PD-L1","volume":"27","author":"Weiss","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.115162_bb0475","series-title":"Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduced T cell proliferation, inflammatory cytokine secretion, and PD-1+ expressing CD4 and CD8 T cells: results from a phase 1 healthy volunteer clinical trial. in DDW Meeting","author":"Luu","year":"2024"},{"key":"10.1016\/j.intimp.2025.115162_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101892","article-title":"PD-1 agonist: a novel therapeutic approach to resolve atherosclerosis","volume":"12","author":"Chen","year":"2024","journal-title":"Results in Chemistry"},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0485","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"65","key":"10.1016\/j.intimp.2025.115162_bb0490","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf4034","article-title":"The double-edged sword: harnessing PD-1 blockade in tumor and autoimmunity","volume":"6","author":"Kuchroo","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0495","series-title":"WILEY 111 RIVER ST, HOBOKEN 07030\u20135774","article-title":"Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody. in ARTHRITIS & RHEUMATOLOGY","author":"Parmley","year":"2023"},{"issue":"7","key":"10.1016\/j.intimp.2025.115162_bb0500","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cbf.3827","article-title":"Structure of PD1 and its mechanism in the treatment of autoimmune diseases","volume":"41","author":"Rezayi","year":"2023","journal-title":"Cell Biochem. Funct."},{"issue":"Supplement_1","key":"10.1016\/j.intimp.2025.115162_bb0505","doi-asserted-by":"crossref","first-page":"i473","DOI":"10.1093\/ecco-jcc\/jjae190.0275","article-title":"P0101 phenotyping of human UC colonic tissue reveals inflammatory pathway gene expression in PD-1+ conventional and regulatory T cells which overlap with those regulated by rosnilimab in a mouse model of colitis","volume":"19","author":"Linggi","year":"2025","journal-title":"J. Crohn's Colitis"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0510","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.13069","article-title":"T peripheral helper cells in autoimmune diseases","volume":"307","author":"Marks","year":"2022","journal-title":"Immunol. Rev."},{"issue":"23","key":"10.1016\/j.intimp.2025.115162_bb0515","doi-asserted-by":"crossref","first-page":"12739","DOI":"10.3390\/ijms222312739","article-title":"The role of the immune system in IBD-associated colorectal cancer: from pro to anti-tumorigenic mechanisms","volume":"22","author":"Frigerio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115162_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-020-00171-2","article-title":"The PD-1: PD-L1 axis in inflammatory arthritis","volume":"5","author":"Canavan","year":"2021","journal-title":"BMC Rheumatology"},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0525","article-title":"Relationship between ulcerative colitis and rheumatoid arthritis: a review","volume":"11","author":"Attalla","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0530","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13075-023-03259-5","article-title":"PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis","volume":"26","author":"Straube","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"20","key":"10.1016\/j.intimp.2025.115162_bb0535","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"10.1016\/j.intimp.2025.115162_bb0540","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102164118","article-title":"Computational design of a synthetic PD-1 agonist","volume":"118","author":"Bryan","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2025.115162_bb0545","doi-asserted-by":"crossref","first-page":"1111005","DOI":"10.3389\/fimmu.2023.1111005","article-title":"The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645699","article-title":"Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases","volume":"12","author":"Zhai","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115162_bb0555","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/0253-7613.103235","article-title":"The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review","volume":"44","author":"Chandrashekara","year":"2012","journal-title":"Indian J. Pharm."},{"key":"10.1016\/j.intimp.2025.115162_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2020.06.001","article-title":"Inhibitory receptor agonists: the future of autoimmune disease therapeutics?","volume":"67","author":"Grebinoski","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0565","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jaci.2022.07.022","article-title":"Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells","volume":"151","author":"Helou","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0570","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1038\/s41467-020-17813-1","article-title":"PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity","volume":"11","author":"Helou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115162_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119034","article-title":"Role of CCL2\/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: latest evidence and therapeutic approaches","volume":"269","author":"Moadab","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2025.115162_bb0580","article-title":"Expression of genes involved in epigenetic modifications in patients with rheumatoid arthritis","volume":"33","author":"Hajizadeh","year":"2022","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0585","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12902-024-01675-5","article-title":"Prevalence and contributing factors of metabolic syndrome in rheumatoid arthritis patients","volume":"24","author":"Bagheri-Hosseinabadi","year":"2024","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0590","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.it.2018.11.006","article-title":"Therapeutic epigenetic reprogramming of trained immunity in myeloid cells","volume":"40","author":"Rodriguez","year":"2019","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0595","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/acsami.2c16458","article-title":"Messenger nanozyme for reprogramming the microenvironment of rheumatoid arthritis","volume":"15","author":"Jia","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"51","key":"10.1016\/j.intimp.2025.115162_bb0600","doi-asserted-by":"crossref","first-page":"70322","DOI":"10.1021\/acsami.4c16772","article-title":"Reactive oxygen and nitrogen species\u2013\u201cNanosweeper\u201d for rheumatoid arthritis Theranostics by macrophage reprogramming","volume":"16","author":"Dong","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.intimp.2025.115162_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867260","article-title":"The role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis","volume":"13","author":"Cutolo","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0610","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1021\/acsnano.2c09127","article-title":"Redox homeostasis strategy for inflammatory macrophage reprogramming in rheumatoid arthritis based on ceria oxide nanozyme-complexed biopolymeric micelles","volume":"17","author":"Zhou","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2025.115162_bb0615","series-title":"NIR-Driven PdH Nanocubes Releasing Hydrogen to Reprogram Inflammatory Microenvironment for Immune Tolerance in Therapy of Rheumatoid Arthritis","first-page":"112203","author":"Li","year":"2025"},{"key":"10.1016\/j.intimp.2025.115162_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.132442","article-title":"Inflammatory macrophage reprogramming strategy of fucoidan microneedles-mediated ROS-responsive polymers for rheumatoid arthritis","volume":"271","author":"Liu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2025.115162_bb0625","doi-asserted-by":"crossref","first-page":"2502880","DOI":"10.1002\/adfm.202502880","article-title":"Double cross-linked hydrogel for intra-articular injection as modality for macrophages metabolic reprogramming and therapy of rheumatoid arthritis","author":"Song","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.intimp.2025.115162_bb0630","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fimmu.2018.00053","article-title":"Role of SLC7A5 in metabolic reprogramming of human monocyte\/macrophage immune responses","volume":"9","author":"Yoon","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0635","doi-asserted-by":"crossref","first-page":"e1887","DOI":"10.1038\/cddis.2015.246","article-title":"The interplay between inflammation and metabolism in rheumatoid arthritis","volume":"6","author":"Chimenti","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.intimp.2025.115162_bb0640","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coi.2017.04.010","article-title":"Metabolic signatures of T-cells and macrophages in rheumatoid arthritis","volume":"46","author":"Weyand","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.306","article-title":"Targeting KAT2A inhibits inflammatory macrophage activation and rheumatoid arthritis through epigenetic and metabolic reprogramming","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"},{"issue":"39","key":"10.1016\/j.intimp.2025.115162_bb0650","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo4250","article-title":"Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications","volume":"8","author":"Xie","year":"2022","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0655","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/ard-2022-223284","article-title":"Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells","volume":"82","author":"Meyer","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2025.115162_bb0660","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2021.11.019","article-title":"M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization","volume":"341","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2025.115162_bb0665","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.actbio.2024.03.006","article-title":"pH-responsive size-adjustable liposomes induce apoptosis of fibroblasts and macrophages for rheumatoid arthritis treatment","volume":"179","author":"Zheng","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.intimp.2025.115162_bb0670","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/annrheumdis-2024-eular.4619","article-title":"POS0170 circulating pathogenic like lymphocytes are mechanistic targets for the TOLEROGENIC re-education in rheumatoid arthritic patients","volume":"83","author":"Leong","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0675","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"11","key":"10.1016\/j.intimp.2025.115162_bb0680","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/rheumatology\/keab355","article-title":"Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors","volume":"60","author":"Fleischmann","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2025.115162_bb0685","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.776879","article-title":"The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis","volume":"12","author":"Fuentelsaz-Romero","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115162_bb0690","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.4049\/jimmunol.1701756","article-title":"IgG immunocomplexes sensitize human monocytes for inflammatory hyperactivity via transcriptomic and epigenetic reprogramming in rheumatoid arthritis","volume":"200","author":"Zhong","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121578","article-title":"Extracellular vesicle-guided in situ reprogramming of synovial macrophages for the treatment of rheumatoid arthritis","volume":"286","author":"Kim","year":"2022","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0700","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-023-01499-0","article-title":"Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms","volume":"8","author":"Jia","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115162_bb0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-018-0948-4","article-title":"Epigenetic modification of mesenchymal stromal cells enhances their suppressive effects on the Th17 responses of cells from rheumatoid arthritis patients","volume":"9","author":"Kim","year":"2018","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0710","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41467-023-36468-2","article-title":"Remodeling articular immune homeostasis with an efferocytosis-informed nanoimitator mitigates rheumatoid arthritis in mice","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0715","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.apsb.2022.08.012","article-title":"Reprogrammed siTNF\u03b1\/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy","volume":"13","author":"Chen","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0720","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.immuni.2021.03.003","article-title":"The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts","volume":"54","author":"Fri\u0161\u010di\u0107","year":"2021","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0725","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2005-07-2800","article-title":"Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+ CD25+ immune regulatory network","volume":"107","author":"de Kleer","year":"2006","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.intimp.2025.115162_bb0730","doi-asserted-by":"crossref","first-page":"14975","DOI":"10.1039\/D4NR02182G","article-title":"Advancements in rheumatoid arthritis therapy: a journey from conventional therapy to precision medicine via nanoparticles targeting immune cells","volume":"16","author":"Laha","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.intimp.2025.115162_bb0735","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jconrel.2024.06.010","article-title":"Nanomedicines targeting activated immune cells and effector cells for rheumatoid arthritis treatment","volume":"371","author":"Deng","year":"2024","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.intimp.2025.115162_bb0740","article-title":"Safety and efficacy of Baricitinib, Upadacitinib, and Sarilumab implementation in moderately-to-severely active rheumatoid arthritis: a systematic review and Meta-analysis of current evidence","volume":"16","author":"Meziridis","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.intimp.2025.115162_bb0745","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/pharmaceutics11110557","article-title":"Extracellular vesicles as natural, safe and efficient drug delivery systems","volume":"11","author":"Villa","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0750","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10717544.2020.1748758","article-title":"Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source","volume":"27","author":"Meng","year":"2020","journal-title":"Drug Deliv."},{"issue":"7","key":"10.1016\/j.intimp.2025.115162_bb0755","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term followup of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"issue":"11","key":"10.1016\/j.intimp.2025.115162_bb0760","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.it.2012.06.004","article-title":"Modulation of immune signalling by inhibitors of apoptosis","volume":"33","author":"Beug","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0765","doi-asserted-by":"crossref","first-page":"1433898","DOI":"10.3389\/fimmu.2024.1433898","article-title":"E3 ubiquitin ligase gene BIRC3 modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes","volume":"15","author":"Meng","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0770","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/rheumatology\/kep467","article-title":"Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment","volume":"49","author":"Smith","year":"2010","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.intimp.2025.115162_bb0775","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ptr.6224","article-title":"The triptolide-induced apoptosis of osteoclast precursor by degradation of cIAP2 and treatment of rheumatoid arthritis of TNF-transgenic mice","volume":"33","author":"Wang","year":"2019","journal-title":"Phytother. Res."},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0780","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.4049\/jimmunol.2100108","article-title":"Selective induction of cell death in human M1 macrophages by smac mimetics is mediated by cIAP-2 and RIPK-1\/3 through the activation of mTORC","volume":"207","author":"Ali","year":"2021","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115162_bb0785","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/JLB.4A0220-114RR","article-title":"Selective killing of human M1 macrophages by Smac mimetics alone and M2 macrophages by Smac mimetics and caspase inhibition","volume":"110","author":"Ali","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2025.115162_bb0790","series-title":"Selective Induction of Cell Death by Smac Mimetics in Primary Human Proinflammatory and Anti-Inflammatory Macrophage Subsets","author":"Ali","year":"2021"},{"issue":"7","key":"10.1016\/j.intimp.2025.115162_bb0795","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1074\/jbc.M112.422410","article-title":"Inhibitor of apoptosis proteins (IAPs) and their antagonists regulate spontaneous and tumor necrosis factor (TNF)-induced proinflammatory cytokine and chemokine production","volume":"288","author":"Kearney","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0800","article-title":"cIAP1\/2 inhibition synergizes with TNF inhibition in autoimmunity by down-regulating IL-17A and inducing Tregs. Science","volume":"5","author":"Kawalkowska","year":"2019","journal-title":"Advances"},{"issue":"8","key":"10.1016\/j.intimp.2025.115162_bb0805","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrc2889","article-title":"IAPs: from caspase inhibitors to modulators of NF-\u03baB, inflammation and cancer","volume":"10","author":"Gyrd-Hansen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115162_bb0810","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.molmed.2014.09.006","article-title":"Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation","volume":"20","author":"Pedersen","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.115162_bb0815","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/14712598.2017.1346078","article-title":"Safety profile of biological therapies for treating rheumatoid arthritis","volume":"17","author":"Ca\u00f1ete","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0820","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2014.05.122","article-title":"Negative feedback regulation of NF-\u03baB-inducing kinase is proteasome-dependent but does not require cellular inhibitors of apoptosis","volume":"450","author":"Gray","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2025.115162_bb0825","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/mr\/roac126","article-title":"Efficacy and safety of anti-TNF multivalent NANOBODY\u00ae compound \u2018ozoralizumab'without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2025.115162_bb0830","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1037983","article-title":"An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis","volume":"13","author":"Vugler","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115162_bb0835","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jconrel.2020.11.041","article-title":"RNA interference-mediated suppression of TNF-\u03b1 converting enzyme as an alternative anti-TNF-\u03b1 therapy for rheumatoid arthritis","volume":"330","author":"Song","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2025.115162_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111845","article-title":"PAMAM dendrimers functionalised with an anti-TNF \u03b1 antibody and chondroitin sulphate for treatment of rheumatoid arthritis","volume":"121","author":"Oliveira","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"issue":"681","key":"10.1016\/j.intimp.2025.115162_bb0845","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti\u2013TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115162_bb0850","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640070","article-title":"Novel bispecific antibody for synovial-specific target delivery of anti-TNF therapy in rheumatoid arthritis","volume":"12","author":"Ferrari","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115162_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111240","article-title":"A novel single domain bispecific antibody targeting VEGF and TNF-\u03b1 ameliorates rheumatoid arthritis","volume":"126","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115162_bb0860","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/1529-0131(199810)41:10<1806::AID-ART12>3.0.CO;2-9","article-title":"Therapeutic actions of cyclosporine and anti-tumor necrosis factor \u03b1 in collagen-induced arthritis and the effect of combination therapy","volume":"41","author":"Williams","year":"1998","journal-title":"Arthritis & Rheumatism: Official Journal of the American College of Rheumatology"},{"key":"10.1016\/j.intimp.2025.115162_bb0865","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-009-1349-y","article-title":"Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha","volume":"29","author":"De Stefano","year":"2010","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0870","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-022-02748-3","article-title":"Plasma interleukin-23 and circulating IL-17A+ IFN\u03b3+ ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis","volume":"24","author":"Millier","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2025.115162_bb0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-021-04248-y","article-title":"Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy","volume":"22","author":"Juli\u00e0","year":"2021","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0880","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-021-02764-y","article-title":"Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment","volume":"19","author":"Ntari","year":"2021","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115162_bb0885","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004480","article-title":"Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis","volume":"10","author":"Tanaka","year":"2024","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.intimp.2025.115162_bb0890","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2025.115162_bb0895","article-title":"The risk of adverse effects of TNF-\u03b1 inhibitors in patients with rheumatoid arthritis: a network meta-analysis","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115162_bb0900","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-023-03178-5","article-title":"Hepatorenal pathologies in TNF-transgenic mouse model of rheumatoid arthritis are alleviated by anti-TNF treatment","volume":"25","author":"Li","year":"2023","journal-title":"Arthritis Res. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:38:23Z","timestamp":1786160303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692501152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":180,"alternative-id":["S156757692501152X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115162","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward immune tolerance in rheumatoid arthritis: Emerging immunotherapies and targets for long-term remission","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115162"}}